269 related articles for article (PubMed ID: 27117181)
1. Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Harrison SJ; Mainwaring P; Price T; Millward MJ; Padrik P; Underhill CR; Cannell PK; Reich SD; Trikha M; Spencer A
Clin Cancer Res; 2016 Sep; 22(18):4559-66. PubMed ID: 27117181
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Richardson PG; Zimmerman TM; Hofmeister CC; Talpaz M; Chanan-Khan AA; Kaufman JL; Laubach JP; Chauhan D; Jakubowiak AJ; Reich S; Trikha M; Anderson KC
Blood; 2016 Jun; 127(22):2693-700. PubMed ID: 27009059
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Spencer A; Harrison S; Zonder J; Badros A; Laubach J; Bergin K; Khot A; Zimmerman T; Chauhan D; Levin N; MacLaren A; Reich SD; Trikha M; Richardson P
Br J Haematol; 2018 Jan; 180(1):41-51. PubMed ID: 29076150
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
[TBL] [Abstract][Full Text] [Related]
5. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.
Alsina M; Trudel S; Furman RR; Rosen PJ; O'Connor OA; Comenzo RL; Wong A; Kunkel LA; Molineaux CJ; Goy A
Clin Cancer Res; 2012 Sep; 18(17):4830-40. PubMed ID: 22761464
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
[TBL] [Abstract][Full Text] [Related]
7. Marizomib for central nervous system-multiple myeloma.
Badros A; Singh Z; Dhakal B; Kwok Y; MacLaren A; Richardson P; Trikha M; Hari P
Br J Haematol; 2017 Apr; 177(2):221-225. PubMed ID: 28387460
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
[TBL] [Abstract][Full Text] [Related]
9. Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Levin N; Spencer A; Harrison SJ; Chauhan D; Burrows FJ; Anderson KC; Reich SD; Richardson PG; Trikha M
Br J Haematol; 2016 Sep; 174(5):711-20. PubMed ID: 27161872
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
11. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Singh AV; Palladino MA; Lloyd GK; Potts BC; Chauhan D; Anderson KC
Br J Haematol; 2010 May; 149(4):550-9. PubMed ID: 20331453
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Dy GK; Thomas JP; Wilding G; Bruzek L; Mandrekar S; Erlichman C; Alberti D; Binger K; Pitot HC; Alberts SR; Hanson LJ; Marnocha R; Tutsch K; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 May; 11(9):3410-6. PubMed ID: 15867242
[TBL] [Abstract][Full Text] [Related]
14. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
Vogl DT; Martin TG; Vij R; Hari P; Mikhael JR; Siegel D; Wu KL; Delforge M; Gasparetto C
Leuk Lymphoma; 2017 Aug; 58(8):1872-1879. PubMed ID: 28140719
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
[TBL] [Abstract][Full Text] [Related]
19. [Proteasome inhibitors in cancer therapy].
Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.
Mohrbacher AM; Yang AS; Groshen S; Kummar S; Gutierrez ME; Kang MH; Tsao-Wei D; Reynolds CP; Newman EM; Maurer BJ
Clin Cancer Res; 2017 Aug; 23(16):4550-4555. PubMed ID: 28420721
[No Abstract] [Full Text] [Related]
[Next] [New Search]
